Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of nurse-led targeted sedation-analgesia management with ventilation duration and sedation quality in mechanically ventilated patients.

PloS one·2026
Same author

Putamen function and MAOA genotype define genetic and neural subtypes of hyperactivity-impulsivity in ADHD.

Journal of affective disorders·2026
Same author

Decoding emotion regulation in adults with ADHD: Subphenotypes, neural correlates, clinical features, and treatment response.

Journal of affective disorders·2026
Same author

The association between nighttime sleep duration and digestive diseases in middle-aged and older population in China: mediating role of depression.

BMC public health·2026
Same author

Metal association and bioaccessibility in rope-derived fibrous microplastics from remote coastal environments of Northern Scotland.

Marine environmental research·2026
Same author

The immune-metabolism interactome in efferocytosis: a new paradigm for the central nervous system diseases revealed by single-cell sequencing analysis.

The Journal of pathology·2026

Related Experiment Video

Updated: Jun 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Dynamic AFP-Defined Disease State Transitions in Hospitalized Patients with Hepatocellular Carcinoma Using the

Qingxian Song1, Huiyi Zhang1,2, Meng Jia1

  • 1Key Laboratory of Molecular Biology for Infectious Diseases, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.

Journal of Hepatocellular Carcinoma
|June 2, 2026
PubMed
Summary

Hepatocellular carcinoma (HCC) disease states are dynamic. Intermediate alpha-fetoprotein (AFP) levels indicate unstable phases, suggesting opportunities for intervention with antiviral therapy and management of liver function.

Keywords:
alpha-fetoproteindisease state transitionshepatocellular carcinomamulti-state Markov model

Related Experiment Videos

Last Updated: Jun 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatology
  • Oncology
  • Biostatistics

Background:

  • Hepatocellular carcinoma (HCC) presents complex disease trajectories, challenging monitoring and prognosis.
  • Alpha-fetoprotein (AFP) is a key biomarker in HCC, but its dynamic changes over time lack explicit modeling.

Purpose of the Study:

  • To model longitudinal transitions between discrete alpha-fetoprotein (AFP) states in hospitalized HCC patients.
  • To assess the impact of clinical factors like antiviral therapy and liver function on AFP state transitions.

Main Methods:

  • Retrospective cohort study of 2,750 HCC patients with 17,076 hospitalizations.
  • Categorization of AFP measurements into four clinical states (S1-S4).
  • Application of a multi-state Markov (MSM) model to analyze transition probabilities, rates, and sojourn times.

Main Results:

  • AFP states S1 (low) and S4 (high) showed relative stability; intermediate states S2 and S3 exhibited frequent bidirectional transitions.
  • Tenofovir disoproxil fumarate (TDF) therapy was linked to a decrease in AFP from S2 to S1.
  • Elevated liver enzymes (ALT, AST) and total bilirubin (TBIL) influenced AFP state transitions, with some associated with decreased likelihood of AFP reduction.

Conclusions:

  • Dynamic modeling of AFP states reveals instability in intermediate phases of HCC, highlighting potential intervention windows.
  • Longitudinal AFP monitoring is valuable for individualized HCC management, beyond single assessments.
  • Antiviral therapy and liver function status significantly impact AFP dynamics in HCC patients.